Health News
Nov 19th, 2026

THE PILL THAT FIGHTS BACK: FDA Clears Roche's Wilserdly for Breast Cancer That Learned to Beat Hormone Therapy

Written By | Health News Agencies
A once-a-day tablet, paired with an older drug, nearly doubled the time before tumours grew in women whose cancer carries a stubborn ESR1 mutation

A once-a-day tablet, paired with an older drug, nearly doubled the time before tumours grew in women whose cancer carries a stubborn ESR1 mutation. The catch: a list price of roughly $270,000 a year, and no proof yet that it helps women live longer.

HEALTH

For hundreds of thousands of women living with advanced breast cancer, the cruelest moment often comes quietly. The hormone pills that held the disease at bay for months or years simply stop working. Scans that were stable start to light up again. And the conversation with the oncologist shifts from "keep going" to "what's next?" This week, the answer to that question got a new name.

On Monday, November 16, 2026, the U.S. Food and Drug Administration approved Wilserdly (giredestrant), a once-daily pill from Swiss drug giant Roche, for adults whose advanced breast cancer has outsmarted earlier hormone treatment and whose tumours carry a mutation in a gene called ESR1. The drug is approved for use together with everolimus, an older targeted medicine, and it comes with a matching blood test to find the patients most likely to benefit.

In the pivotal trial, women and men taking the new combination went a median of 10 months before their cancer grew or they died, compared with just 5.5 months for those given a standard hormone drug plus everolimus. That is close to double the time, and a 62 percent cut in the risk of the disease advancing. 
"Marks a pivotal leap forward in addressing aggressive, treatment-resistant breast cancer," is how Teresa Graham, chief executive of Roche Pharmaceuticals, described the decision in the company's announcement.

Could A Daily Pill Help Prevent Breast Cancer Recurrence? Roche's Promising  Experimental Drug Awaits FDA Approval | Health and Me

The Mutation That Hijacks the Switch

To understand why this matters, you need to understand the enemy. Roughly 70 percent of all breast cancers are what doctors call hormone receptor-positive and HER2-negative. In plain terms, these tumours are fuelled by the body's own oestrogen. Each cancer cell is studded with oestrogen receptors, tiny docking stations that, when switched on, tell the cell to grow and divide. 
For decades, the backbone of treatment has been to starve the cancer of that signal, either by lowering oestrogen levels or by blocking the receptor. Today that is usually paired with a newer class of drugs called CDK4/6 inhibitors. The approach works, often for years. But cancer is a master of adaptation. 
Under the pressure of treatment, some tumours develop mutations in ESR1, the gene that builds the oestrogen receptor itself. A mutated receptor can stay switched "on" even when there is little or no oestrogen around. It is the biological equivalent of a car whose accelerator is jammed to the floor. Starving the engine of fuel no longer stops it.

According to Roche, up to 40 percent of patients with hormone receptor-positive metastatic breast cancer develop these ESR1 mutations, which are linked to resistance to standard hormone therapy. And the company says the cancer often has a second escape route: switching on a growth pathway known as PI3K/AKT/mTOR while still depending on the oestrogen receptor. 
That two-pronged escape is exactly what Wilserdly and everolimus are designed to shut down together.

How the New Pill Works

Giredestrant belongs to a family of drugs called selective oestrogen receptor degraders, or SERDs. Rather than just sitting on the receptor and blocking it, a SERD latches on and marks the receptor for destruction, so the cell breaks it down. Roche describes giredestrant as a "full antagonist", meaning it is designed to shut the receptor down completely rather than partly. 
The first drug in this class, fulvestrant, has been used for years, but it must be given as intramuscular injections. Giredestrant is a pill, taken at a dose of 30 milligrams once a day, with or without food.

Its partner, everolimus, blocks mTOR, a key switch in that second growth pathway. The idea is simple: hit the jammed accelerator and cut the backup engine at the same time. 
Alongside the drug, the FDA also authorised the FoundationOne Liquid CDx blood test, which detects fragments of tumour DNA circulating in a patient's blood. That "liquid biopsy" is how doctors will identify which patients have the ESR1 mutation and qualify for the new treatment, without needing to cut out fresh tissue.

Inside the evERA Trial

The approval rests on a Phase III study called evERA Breast Cancer, published this year in the New England Journal of Medicine. 
The trial enrolled 373 adults with ER-positive, HER2-negative advanced breast cancer whose disease had progressed after earlier treatment that included a CDK4/6 inhibitor. Of those, 207 had ESR1 mutations. Everyone in the study received everolimus. Half were randomly assigned to add giredestrant; the other half added a standard hormone therapy chosen by their doctor.

The headline numbers for patients with ESR1 mutations were striking:

  • Median progression-free survival of 10 months with the giredestrant combination, versus 5.5 months with standard hormone therapy plus everolimus.
  • A 62 percent reduction in the risk of progression or death, with a hazard ratio of 0.38. Statistically, the result was highly significant (p<0.0001).
  • Tumours shrank in 27 percent of patients on the giredestrant combination, compared with 14 percent in the comparison group.

There is one important line that patients should not skip, though. The FDA said it is still too early to know whether the combination helps people live longer. Overall survival is one of the trial's key secondary goals, and that data is not yet mature. For now, the proven benefit is more time with the cancer held in check.

The Side Effects

No cancer drug is free, in either sense of the word. The most common side effects reported with the combination included inflammation of the mouth or of lung tissue, rash, fatigue, diarrhoea, muscle and bone pain, and nausea. Some patients also had abnormal blood test results. 
The drug's label carries warnings for two specific risks: an abnormally slow heart rate, known as bradycardia, and harm to a developing baby. Women who could become pregnant will need to discuss contraception with their care team.

Many of the mouth and lung problems are familiar to oncologists from everolimus itself, which has been used in breast cancer for more than a decade. Doctors will be watching closely for these and adjusting doses when needed.

The $270,000 Question

Then there is the price tag. According to the company's statement to the health news outlet STAT, the list price is about $270,000 per year. That is in line with many modern cancer drugs in the United States, but it is a staggering figure for families, and it will put pressure on insurers and on patients' out-of-pocket costs.

For Roche, the stakes are enormous. The company has said giredestrant could become its best-selling product ever. Analysts cited in news coverage estimate peak yearly sales ranging from a few billion dollars to more than $10 billion, if the drug wins approval for other kinds of breast cancer.

And the next test comes fast. The FDA is due to decide by November 30, 2026, on a second application, based on the lidERA trial, to use giredestrant after surgery in people with stage I to III ER-positive, HER2-negative breast cancer who have an intermediate to high risk of their cancer coming back. The agency accepted that application under Priority Review.

If that is approved, Roche says Wilserdly would become the first SERD cleared in both the early-stage and advanced settings, and the first new hormone therapy for use after surgery in more than 20 years. That would move the drug from the last lines of treatment to the very beginning, potentially reaching far more patients.

Researchers Uncover How Resistance to Treatment Can Develop in Breast Cancer  Cells

A Crowded, Competitive Race

Wilserdly is not the only pill of its kind. Oral SERDs have become one of the hottest races in cancer drug development. Elacestrant (sold as Orserdu) was the first to reach the U.S. market, in 2023, for ESR1-mutated advanced breast cancer, and Eli Lilly's imlunestrant followed in 2025. AstraZeneca and others are pursuing their own candidates.
What sets the Roche approval apart is the pairing with everolimus and the specific group studied: patients whose cancer had already progressed after CDK4/6 inhibitors, which is now the standard first treatment for advanced disease. That is a large and growing group of patients with limited options.

Roche is also running a long list of further trials, including pionERA, heredERA (in HER2-positive disease alongside Roche's Phesgo), and two studies, novERA and kalitERA, focused on how well patients tolerate the drug and stick with it day to day. Filings outside the United States are also under way.

Expert Perspective

Dr. Erica L. Mayer, director of breast cancer clinical research at Dana-Farber Cancer Institute in Boston, put the patient experience front and centre. People whose cancer has stopped responding to hormone therapy, she said, "often face difficult choices and deteriorating quality of life as options narrow."

The new combination, she said in Roche's announcement, is about "offering patients prolonged disease control through a fully oral therapeutic option."
That word "oral" matters more than it might seem. For many patients, being able to take treatment at home, rather than travelling for injections or infusions, is a real quality-of-life gain, especially for those who are working, caring for children, or living far from a cancer centre.

Dr. Levi Garraway, Roche's chief medical officer and head of global product development, acknowledged the scale of the problem the drug is trying to solve, saying "the development of resistance to endocrine therapy remains a substantial challenge." 
Independent observers will be cautious until survival data arrives. A longer stretch without progression is meaningful, but the gold standard is whether patients live longer, and live well. The evERA investigators will continue following patients to answer that.

What This Means for You

If you or someone you love has advanced hormone receptor-positive, HER2-negative breast cancer, here is what to take away.
First, ask about ESR1 testing. The new treatment only applies to tumours with an ESR1 mutation, and those mutations often appear later, after a patient has been on hormone therapy. A simple blood test, such as the FoundationOne Liquid CDx test authorised alongside the drug, can check for it. If you were tested a long time ago, it may be worth asking whether a repeat test makes sense when your cancer progresses.

Second, know where it fits. Wilserdly is approved for people whose cancer came back during or after hormone therapy following surgery, or whose disease progressed on at least one hormone-based treatment in the metastatic setting. It is not, yet, a first treatment for newly diagnosed early breast cancer. That could change after the FDA's November 30 decision. 
Third, talk about side effects and heart health. Because of the warning about slow heart rate, your doctor will want to know about any heart conditions and other medicines you take.

Fourth, ask about cost early. With a list price around $270,000 a year, coverage and assistance programmes matter. Hospital financial counsellors and the manufacturer's patient support services can help. 
And finally, remember that one statistic does not describe one person. A median of 10 months means half of patients did better than that and half did worse. Your own situation, previous treatments, and overall health will shape what is right for you.

The Bottom Line

Breast cancer is diagnosed in about 2.3 million women around the world each year and kills about 670,000, according to the World Health Organization. Most of those cancers are driven by hormones, and many eventually learn to resist the drugs designed to starve them.

Wilserdly will not change that overnight. It is not a cure, its survival benefit is unproven, and its price will be a barrier for many. But for patients whose cancer has found a way around the standard playbook, it offers something oncologists value enormously: another effective, evidence-backed option that can be taken at home, with a pill and a glass of water. And with a second FDA decision only days away, the story of this little tablet may be only just beginning.

Published By | Features Editor

More Related News